Common Contracts
10 similar Warrant Agreement contracts by Genocea Biosciences, Inc., Gritstone Bio, Inc., Gritstone Oncology, Inc., others
WARRANT NO. 2024-[●] NUMBER OF SHARES: [●] (subject to adjustment hereunder)Warrant Agreement • April 2nd, 2024 • Gritstone Bio, Inc. • Biological products, (no disgnostic substances) • New York
This Warrant (the “Warrant”) is issued by Gritstone bio, Inc., a Delaware corporation (the “Company”), to [●], or its registered assigns (including any successors or assigns, the “Holder”), and is subject to the terms and conditions set forth below. The Warrants are offered and sold by the Company pursuant to the Prospectus Supplement, dated April 1, 2024 (as described in the Registration Statement). “Registration Statement” means the Company’s registration statement on Form S-3, as amended (File No. 333-263455). As of the Date of Issuance the Warrant Shares are issuable under the Registration Statement. Accordingly, the Warrant and, assuming issuance pursuant to the Registration Statement or an exchange meeting the requirements of Section 3(a)(9) of the Securities Act of 1933, as amended (the “Securities Act”) as in effect on the Date of Issuance, the Warrant Shares, are not “restricted securities” under Rule 144 promulgated under the Securities Act as of the Date of Issuance.
WARRANT NO. 2022-[⚫] NUMBER OF SHARES: [⚫] (subject to adjustment hereunder)Warrant Agreement • October 25th, 2022 • Gritstone Bio, Inc. • Biological products, (no disgnostic substances) • New York
This Warrant (the “Warrant”) is issued by Gritstone bio, Inc., a Delaware corporation (the “Company”), to [⚫], or its registered assigns (including any successors or assigns, the “Holder”), and is subject to the terms and conditions set forth below. The Warrant is being issued pursuant to that certain Securities Purchase Agreement, dated as of October 24, 2022, among the Company and the purchasers signatory thereto, as amended and/or restated from time to time (the “Purchase Agreement”). Capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Purchase Agreement.
SERIES B WARRANT TO PURCHASE SHARES OF COMMON STOCK OF IMMUNOME, INC.Warrant Agreement • April 26th, 2021 • Immunome Inc. • Pharmaceutical preparations • New York
This Series B Warrant (the “Warrant”) is issued by Immunome, Inc., a Delaware corporation (the “Company”), to [________] (including any successors or assigns, the “Holder”), and is subject to the terms and conditions set forth below. The Warrant is being issued pursuant to a Warrant Agreement between the Company and American Stock Transfer & Trust Company, LLC (the “Warrant Agent”). Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement dated as of [__], 2021, among the Company and the purchasers signatory thereto (the “Purchase Agreement”).
WARRANT NO. 2020-[●] NUMBER OF SHARES: [●] (subject to adjustment hereunder)Warrant Agreement • December 28th, 2020 • Gritstone Oncology, Inc. • Biological products, (no disgnostic substances) • New York
This Warrant (the “Warrant”) is issued by Gritstone Oncology, Inc., a Delaware corporation (the “Company”), to [●], or its registered assigns (including any successors or assigns, the “Holder”), and is subject to the terms and conditions set forth below. The Warrant is being issued pursuant to that certain Securities Purchase Agreement, dated as of December 22, 2020, among the Company and the purchasers signatory thereto, as amended and/or restated from time to time (the “Purchase Agreement”). Capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Purchase Agreement.
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE...Warrant Agreement • July 22nd, 2020 • Genocea Biosciences, Inc. • Biological products, (no disgnostic substances) • New York
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE...Warrant Agreement • July 22nd, 2020 • Genocea Biosciences, Inc. • Biological products, (no disgnostic substances) • New York
CLASS A WARRANT TO PURCHASE SHARES OF COMMON STOCK OF SYNLOGIC, INC.Warrant Agreement • June 12th, 2019 • Synlogic, Inc. • Pharmaceutical preparations • New York
This Class A Warrant (the “Warrant”) is issued by Synlogic, Inc., a Delaware corporation (the “Company”), to GINKGO BIOWORKS, INC., or its registered assigns (including any successors or assigns, the “Holder”), and is subject to the terms and conditions set forth below. The Warrant is being issued pursuant to that certain Subscription Agreement by and among the Company and the Holder dated as of June 11, 2019 (the “Subscription Agreement”).
CLASS B WARRANT TO PURCHASE SHARES OF COMMON STOCK OFWarrant Agreement • February 28th, 2019 • Genocea Biosciences, Inc. • Biological products, (no disgnostic substances) • New York
This Class B Warrant (the “Warrant”) is issued by Genocea Biosciences, Inc., a Delaware corporation (the “Company”), to [________], or its registered assigns (including any successors or assigns, the “Holder”), and is subject to the terms and conditions set forth below. The Warrant is being issued pursuant to a Warrant Agreement between the Company and Computershare Inc., a Delaware corporation (“Computershare”), and its fully owned subsidiary Computershare Trust Company, N.A., a national banking association (collectively with Computershare, the “Warrant Agent”).
CLASS B WARRANT TO PURCHASE SHARES OF COMMON STOCK OFWarrant Agreement • February 12th, 2019 • Genocea Biosciences, Inc. • Biological products, (no disgnostic substances) • New York
This Class B Warrant (the “Warrant”) is issued by Genocea Biosciences, Inc., a Delaware corporation (the “Company”), to [________], or its registered assigns (including any successors or assigns, the “Holder”), and is subject to the terms and conditions set forth below. The Warrant is being issued pursuant to a Warrant Agreement between the Company and Computershare Inc., a Delaware corporation (“Computershare”), and its fully owned subsidiary Computershare Trust Company, N.A., a national banking association (collectively with Computershare, the “Warrant Agent”).
CLASS B PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK OFWarrant Agreement • February 12th, 2019 • Genocea Biosciences, Inc. • Biological products, (no disgnostic substances) • New York
This Class B Warrant (the “Warrant”) is issued by Genocea Biosciences, Inc., a Delaware corporation (the “Company”), to [________], or its registered assigns (including any successors or assigns, the “Holder”), and is subject to the terms and conditions set forth below. The Warrant is being issued pursuant to a Warrant Agreement between the Company and Computershare Inc., a Delaware corporation (“Computershare”), and its fully owned subsidiary Computershare Trust Company, N.A., a national banking association (collectively with Computershare, the “Warrant Agent”).
